%0 Journal Article
%T Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas
%A Agnieszka Dansonka-Mieszkowska
%A Aneta Balabas
%A Iwona K. Rzepecka
%A Joanna Chodzynska
%A Joanna Moes-Sosnowska
%A Jolanta Kupryjanczyk
%A Lukasz M. Szafron
%A Piotr Sobiczewski
%A Renata Lotocka
%J Archive of "Cancer Biology & Therapy".
%D 2019
%R 10.1080/15384047.2019.1579955
%X Objective: DNA repair pathways are potential targets of molecular therapy in cancer patients. The FANCD2, BRIP1, BRCA1/2, and FANCF genes are involved in homologous recombination DNA repair, which implicates their possible role in cell response to DNA-damaging agents. We evaluated a clinical significance of pre-treatment expression of these genes at mRNA level in 99 primary, advanced-stage ovarian carcinomas from patients, who later received taxane-platinum (TP) or platinum-cyclophosphamide (PC) treatment
%K FANCD2
%K BRIP1
%K FANCJ
%K BRCA1
%K BRCA2
%K FANCF
%K TP53
%K ovarian cancer
%K DNA repair
%K gene expression
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606037/